Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 5/20 | 0.37 |
| ▸ | KIT | P10721 | 3/20 | 0.37 |
| ▸ | PDE4A | P27815 | 6/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16320574 | 0.88 | CCNA2 (0.40) | CSF1RKITMEN1KMT2ACCNA2 | |
| SCHEMBL14385440 | 0.77 | CSF1R (0.49) | CSF1RKIT | |
| SCHEMBL16320164 | 0.76 | CSF1R (0.37) | CSF1RKIT | |
| SCHEMBL3977368 | 0.75 | KDM5B (0.31) | — | |
| SCHEMBL3977044 | 0.75 | TBK1 (0.34) | CSF1RKIT | |
| SCHEMBL16320664 | 0.75 | CSF1R (0.31) | CSF1RKIT | |
| SCHEMBL15738540 | 0.74 | CSF1R (0.46) | CSF1RKIT | |
| SCHEMBL16341487 | 0.73 | CSF1R (0.38) | CSF1RKIT | |
| SCHEMBL3976921 | 0.70 | CSF1R (0.36) | CSF1RKIT | |
| SCHEMBL4338263 | 0.70 | CSF1R (0.41) | CSF1RKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394289-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-19 | — | — | US | disclosed |
| EP-2016070-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-13 | — | — | EP | disclosed |
| US-20140378457-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378457-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | CSF1R 59/4885KIT 108/4885PDE4A 3957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.